姓名 | 職稱 | 持有股份 | 代表法人 |
---|---|---|---|
Wang,Xue-Hong | Chairman | 3.87% | |
Chen,Wen-Qi | Director | 2.69% | |
Zhuo,Huo-Tu | Director | 0.01% | |
David Bruce Yoffie | Director | 0.00% | |
Lin,Zhen-Guo | Independent Director | 0.00% | |
Vincent Thai | Independent Director | 0.00% | |
Michael C. Lu | Independent Director | 0.00% | |
Xie,Hong-Zhong | Independent Director | 0.00% |
項目 | 2024 | 2023 | 2022 |
---|---|---|---|
Operating income | 3,080,984 | 4,417,932 | 4,408,823 |
Operating cost | 1,827,140 | 2,594,222 | 2,678,845 |
Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
Operating gross profit (loss) | 1,253,844 | 1,823,710 | 1,729,978 |
Unrealized profit (loss) on sales of goods | - | - | - |
Realized profit (loss) on sales of goods | - | - | - |
Operating gross profit (loss), net | 1,253,844 | 1,823,710 | 1,729,978 |
Operating expenses | 5,893,181 | 6,118,391 | 6,133,809 |
Other gain (loss), net | - | - | - |
Operating profit (loss) | -4,639,337 | -4,294,681 | -4,403,831 |
Non-operating income and expenses | 1,222,552 | 896,003 | 989,780 |
Net profit (loss) before tax | -3,416,785 | -3,398,678 | -3,414,051 |
Income tax expense (benefits) | 1,503 | -2,921 | -2,268 |
Net profit (loss) of ongoing business for the current period | -3,418,288 | -3,395,757 | -3,411,783 |
Profit (loss) of closed units | - | - | - |
Profit (loss) of non-jointly controlled equity before merger | - | - | - |
Net profit (loss) for the current period | -3,418,288 | -3,395,757 | -3,411,783 |
Other comprehensive profit (loss), net | 2,019,540 | 506,133 | 1,543,006 |
Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
Total comprehensive profit and loss for the current period | -1,398,748 | -2,889,624 | -1,868,777 |
Net profit (loss) attributable to owners of parent company | -3,418,288 | -3,395,757 | -3,411,783 |
Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
Net profit (loss) attributable to non-controlling interests | - | - | 0 |
Comprehensive profit (loss) attributable to owners of parent company | -1,398,748 | -2,889,624 | -1,868,777 |
Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
Comprehensive profit (loss) attributable to non-controlling interests | - | - | 0 |
Basic earnings per share (yuan) | -4 | -4 | -4 |
項目 | 2024 | 2023 | 2022 |
---|---|---|---|
Net cash inflow (outflow) from operating activities | -2,537,933 | -4,049,032 | -3,740,037 |
Net cash inflows (outflows) from investing activities | 752,571 | -4,894,019 | -844,083 |
Net cash inflow (outflow) from financing activities | 2,525,201 | 3,286,374 | 4,955,638 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1,060,007 | 348,910 | 996,828 |
Increase (decrease) in cash and cash equivalents in the current period | 1,799,846 | -5,307,767 | 1,368,346 |
Beginning balance of cash and cash equivalents | 12,439,363 | 17,747,130 | 16,576,907 |
Ending balance of cash and cash equivalents | 14,239,209 | 12,439,363 | 17,945,253 |
項目 | 2024 | 2023 | 2022 |
---|---|---|---|
Current asset | 26,996,749 | 26,900,804 | 27,585,609 |
Non-current asset | 19,234,721 | 18,682,504 | 18,854,627 |
Total asset | 46,231,470 | 45,583,308 | 46,440,236 |
Current liability | 12,739,356 | 13,501,340 | 13,727,123 |
Non-current liability | 12,063,845 | 9,276,840 | 7,153,953 |
Total liability | 24,803,201 | 22,778,180 | 20,881,076 |
share capital | 8,335,340 | 8,320,380 | 8,295,153 |
Equity - secruity token | - | - | - |
capital reserve | 16,277,565 | 16,270,636 | 16,160,271 |
retained earning | -794,015 | 1,571,162 | 4,909,467 |
Other equity | -2,390,621 | -3,357,050 | -3,805,731 |
Treasury stock | - | - | - |
Total equity attributable to owners of parent company | 21,428,269 | 22,805,128 | 25,559,160 |
Equity attributable to former owner of business combination under common control | - | - | - |
Equity attributable to non-controlling interest before business merger under common control | - | - | - |
Non-controlling interests | - | - | 0 |
Total Equity | 21,428,269 | 22,805,128 | 25,559,160 |
Share capital awaiting retirement (unit: share) | - | - | - |
Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
Net asset value per share | 25 | 27 | 30 |
標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
---|---|---|---|---|
Virti互動式360影片教案設計製作工作坊 | 國立臺灣大學 | 113/05/21 | 300000.0 | 是 |
XR-CPR軟體授權採購案 | 臺中榮民總醫院 | 113/05/16 | 745000.0 | 是 |
113年度智慧XR警勤訓練建置案 | 內政部警政署 | 113/04/30 | 否 | |
臺大醫學院VR頭戴式顯示器組 | 國立臺灣大學 | 113/04/02 | 280000.0 | 是 |
「5G移動專網設備租用」採購案 | 南臺學校財團法人南臺科技大學 | 113/02/06 | 5000000.0 | 是 |
「教育元宇宙平台服務之使用費」勞務採購案 | 國立屏東大學 | 113/01/11 | 2400000.0 | 是 |
多元教材推動平台 | 臺北榮民總醫院 | 112/12/26 | 否 | |
多元教材線上學習網維護含虛擬實境擴增資訊服務 | 臺北榮民總醫院 | 112/12/07 | 189000.0 | 是 |
虛擬實境教案建置編輯平台及相關硬體設備 | 國立臺灣大學 | 112/10/26 | 220000.0 | 是 |
VR教學平台互動式360影片教案研改 | 國防醫學院 | 112/10/18 | 292000.0 | 是 |
護理學系籌備處採購解剖生理學虛擬實境(VR)教材 | 國立暨南國際大學 | 112/07/14 | 510000.0 | 是 |
「教育元宇宙平台服務之使用」勞務採購案 | 國立屏東大學 | 112/04/19 | 8400000.0 | 是 |
「新竹市文化局數位雙生科普實驗室內容設計委託專業服務案」第二次契約變更 | 新竹市文化局 | 112/01/31 | 230400.0 | 是 |
創新教學軟體與培訓課程採購 | 國立臺灣大學 | 111/11/29 | 930000.0 | 是 |
「新竹市文化局數位雙生科普實驗室內容設計委託專業服務案」第一次契約變更 | 新竹市文化局 | 111/11/09 | 2557700.0 | 是 |
人體解剖訓練器套組 | 國立臺灣大學 | 111/11/01 | 530000.0 | 是 |
3D人體解剖教學軟體及虛擬實境設備 | 國立臺灣師範大學 | 111/10/27 | 312000.0 | 是 |
111年度長照大樓護理之家虛擬實境(VR)設備採購案 | 臺中榮民總醫院嘉義分院 | 111/10/25 | 107000.0 | 是 |
未來教室VR設備採購 | 國立臺灣大學 | 111/10/12 | 820000.0 | 是 |
高雄百點集章行動NFT製作勞務採購案 | 高雄市政府文化局 | 111/08/05 | 760000.0 | 是 |
新竹市文化局數位雙生科普實驗室內容設計委託專業服務案 | 新竹市文化局 | 111/07/28 | 23420000.0 | 是 |
虛擬實境電子書 | 中臺科技大學 | 111/07/05 | 125000.0 | 是 |
虛擬實境(VR)教學及教案製作軟體及硬體設備乙批整合採購 | 國立嘉義大學 | 111/06/23 | 340000.0 | 是 |
3D Organon 人體解剖教學系統 | 大葉大學 | 111/06/01 | 2460000.0 | 是 |
虛擬實境牙醫學訓練系統 | 中國醫藥大學 | 111/06/01 | 否 | |
教案設計製作工作坊18小時及6個一年期Virti帳號 | 國立臺灣大學醫學院附設醫院 | 110/12/13 | 268000.0 | 是 |
110年度虛擬實境森林開發工具曁生理回饋分析儀器組採購案 | 國立臺灣大學生物資源暨農學院實驗林管理處 | 110/11/04 | 1346000.0 | 是 |
互動式360影片教案平台 | 國防醫學院 | 110/09/16 | 675000.0 | 是 |
內政部警政署110年度智慧XR警勤訓練建置案 | 內政部警政署 | 110/06/01 | 否 |
日期 | 違反法規法條 | 罰鍰金額 |
---|---|---|
2021/12/17 | Paragraph 5, Article 30 of the Labor Standards Act | 120,000 |
2021/04/16 | Paragraph 6, Article 30 of the Labor Standards Act | 240,000 |
2021/04/16 | Article 24 of the Labor Standards Act | 48,000 |
2020/12/03 | Paragraph 1, Article 36 of the Labor Standards Act | 50,000 |
2019/06/18 | Paragraph 6, Article 30 of the Labor Standards Act | |
2019/03/08 | Paragraph 1, Article 24 of the Labor Standards Act | |
2018/01/08 | Paragraph 2, Article 22 of the Labor Standards Act | |
2017/10/11 | Paragraph 1, Article 6 of the Occupational Safety and Health Act | |
2017/04/20 | Article 39 of the Labor Standards Act | |
2016/12/10 | Article 37 of the Labor Standards Act | |
2016/11/06 | Article 24 of the Labor Standards Act | |
2016/11/06 | Paragraph 2, Article 32 of the Labor Standards Act | |
2016/05/06 | Article 36 of the Labor Standards Act | |
2016/05/06 | Paragraph 2, Article 32 of the Labor Standards Act | |
2016/03/06 | Paragraph 5, Article 30 of the Labor Standards Act | |
2016/01/10 | Paragraph 2, Article 32 of the Labor Standards Act |